These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26893565)

  • 1. Depot-medication compliance for patients with psychotic disorders: the importance of illness insight and treatment motivation.
    Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Mulder CL
    Neuropsychiatr Dis Treat; 2016; 12():269-74. PubMed ID: 26893565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of financial incentives on patients' motivation for treatment: results of "Money for Medication," a randomised controlled trial.
    Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AFT; Mulder CL
    BMC Psychiatry; 2018 May; 18(1):144. PubMed ID: 29793451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial.
    Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Staring AB; Mulder CL
    Lancet Psychiatry; 2017 Mar; 4(3):199-207. PubMed ID: 28236956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders.
    Noordraven EL; Audier CH; Staring AB; Wierdsma AI; Blanken P; van der Hoorn BE; Roijen LH; Mulder CL
    BMC Psychiatry; 2014 Dec; 14():343. PubMed ID: 25438877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethical acceptability of offering financial incentives for taking antipsychotic depot medication: patients' and clinicians' perspectives after a 12-month randomized controlled trial.
    Noordraven EL; Schermer MHN; Blanken P; Mulder CL; Wierdsma AI
    BMC Psychiatry; 2017 Aug; 17(1):313. PubMed ID: 28851345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral.
    Patel MX; de Zoysa N; Bernadt M; David AS
    J Clin Psychiatry; 2008 Oct; 69(10):1548-56. PubMed ID: 19192437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term depot antipsychotics. A risk-benefit assessment.
    Barnes TR; Curson DA
    Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?
    Bloch Y; Mendlovic S; Strupinsky S; Altshuler A; Fennig S; Ratzoni G
    J Clin Psychiatry; 2001 Nov; 62(11):855-9. PubMed ID: 11775044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone (depot) for schizophrenia.
    Sampson S; Hosalli P; Furtado VA; Davis JM
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD004161. PubMed ID: 27078222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders.
    Janssen B; Gaebel W; Haerter M; Komaharadi F; Lindel B; Weinmann S
    Psychopharmacology (Berl); 2006 Aug; 187(2):229-36. PubMed ID: 16710714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depot haloperidol decanoate for schizophrenia.
    Quraishi S; David A
    Cochrane Database Syst Rev; 2000; 1999(2):CD001361. PubMed ID: 10796438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial compliance with antipsychotic medication is common in patients with schizophrenia.
    Rummel-Kluge C; Schuster T; Peters S; Kissling W
    Aust N Z J Psychiatry; 2008 May; 42(5):382-8. PubMed ID: 18473256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Motivational interviewing for cannabis users with psychotic disorders].
    Bonsack C; Montagrin Y; Favrod J; Gibellini S; Conus P
    Encephale; 2007 Oct; 33(5):819-26. PubMed ID: 18357854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative symptoms of schizophrenia and compliance with medication.
    Tattan TM; Creed FH
    Schizophr Bull; 2001; 27(1):149-55. PubMed ID: 11215543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders.
    Quraishi S; David A
    Cochrane Database Syst Rev; 2000; (2):CD001470. PubMed ID: 10796442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychotic relapse and associated factors among patients attending health services in Southwest Ethiopia: a cross-sectional study.
    Fikreyesus M; Soboka M; Feyissa GT
    BMC Psychiatry; 2016 Oct; 16(1):354. PubMed ID: 27765033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.